Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (9433)	11/18/2002 8:15:15 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 9719

David, Obesity is not only MLNM big target, it is big target for all pharmas and dozens bios. It is (in combination with diabetes) by far the biggest market opportunity. MLNM has 50:50 collaboration with Abbott in metabolic (obesity/diabetes) filed. Their first candidate, MLN4760, is carboxypeptidase inhibitor (related to ACE) in PI for obesity. However, this is only small part of very broad collaboration. First, MLNM did have genomic collaboration with Roche on identifying and selecting possible targets. This collaboration ended, and two years later they form Abbott deal. So, it is not how much they are actually spending on it (the bigger the better), it is what will come out of it. Miljenko PS: Not to hide, REGN is my current pick for obesity franchise.